Valeo Financial Advisors LLC raised its stake in shares of Novartis AG (NYSE:NVS) by 15.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,519 shares of the company’s stock after acquiring an additional 856 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Novartis were worth $547,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in NVS. Cetera Investment Advisers bought a new stake in Novartis during the 2nd quarter valued at $241,000. Narwhal Capital Management boosted its position in Novartis by 6.4% during the 3rd quarter. Narwhal Capital Management now owns 53,160 shares of the company’s stock valued at $4,564,000 after acquiring an additional 3,200 shares in the last quarter. Founders Capital Management boosted its position in Novartis by 4.6% during the 3rd quarter. Founders Capital Management now owns 33,660 shares of the company’s stock valued at $2,890,000 after acquiring an additional 1,485 shares in the last quarter. Fisher Asset Management LLC boosted its position in Novartis by 2.0% during the 3rd quarter. Fisher Asset Management LLC now owns 6,632,984 shares of the company’s stock valued at $569,442,000 after acquiring an additional 127,049 shares in the last quarter. Finally, Hall Capital Management Co. Inc. boosted its position in Novartis by 8.8% during the 3rd quarter. Hall Capital Management Co. Inc. now owns 12,950 shares of the company’s stock valued at $1,112,000 after acquiring an additional 1,045 shares in the last quarter. 10.96% of the stock is currently owned by institutional investors and hedge funds.
Shares of Novartis AG (NYSE:NVS) opened at $85.32 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. The firm has a market capitalization of $201,410.11, a price-to-earnings ratio of 26.32, a PEG ratio of 2.02 and a beta of 0.73. Novartis AG has a 52-week low of $72.67 and a 52-week high of $94.19.
Novartis (NYSE:NVS) last posted its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.04. The firm had revenue of $12.92 billion during the quarter, compared to analysts’ expectations of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.14 EPS. research analysts expect that Novartis AG will post 5.36 earnings per share for the current fiscal year.
Several analysts have issued reports on NVS shares. Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research report on Wednesday, December 27th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. Novartis currently has an average rating of “Hold” and an average target price of $85.32.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.